EyePoint Pharmaceuticals investigated over misleading wet AMD trial results

NEW YORK, Sept. 3, 2026 /CourierPR/ -- The investigation stems from a press release issued by EyePoint on August 17, 2026, announcing the results of the LUGANO trial, a pivotal Phase 3 clinical study for DURAVYU™ (vorolanib intravitreal insert) as a treatment for wet age-related macular degeneration (wet AMD). According to the press release, the change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals’ Eylea) was not achieved across the entire dataset.

Following the release of this news, EyePoint’s stock price plummeted by $9.88 per share, representing a 66.98% decline, closing at $4.87 per share on the same day. This sharp drop in value has raised concerns among investors about potential misrepresentations or fraudulent practices by the company and its officers or directors.

Pomerantz Law Firm, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leading firm in securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, the firm has been at the forefront of class action lawsuits, focusing on cases involving breaches of fiduciary duty and corporate misconduct. Over the past 85 years, Pomerantz has secured numerous multimillion-dollar damage awards for its clients.